Therapeutics Segment to Bolster Human microbiome Market Growth During 2023–2031
According to our new research study on "Human microbiome Market Forecast to 2031 Global Analysis – by Type, Structure, Application, and End User," the market is expected to grow from US$ 4.84 billion by 2031 from US$ 1.7 billion in 2023; it is estimated to grow at a CAGR of 20.8% during 2023–2031. The report highlights trends prevailing in the market, and drivers and restraints pertaining to the market growth.
In recent years, microbiome-based therapeutics, also known as microbiome modulators, have made rapid advances. Several promising candidates have moved forward through the clinical pipeline. For instance, in April 2023, Ferring Pharmaceuticals' VOWST, the first fecal microbiota product taken orally, was approved for preventing recurrence of Clostridioides difficile (C. difficile) infection in patients 18 years and older, following antibiotic treatment for recurrent infection. Similarly, in November 2022, Seres Therapeutics' Rebyota got approval from the US Food and Drug Administration (FDA). Both products promise to provide safe and effective treatments for patients with recurrent Clostridioides difficile infection (rCDI)..
Robust Investment in Research and Development is Propelling the Growth of Human microbiome Market.
The potential of the human microbiome to transform healthcare industry has led to a recent surge in investments in research and development. The trillions of bacteria, fungi, and viruses that live in and on the human body make up the human microbiome, which is essential to good health as well as the prevention and treatment of diseases. The development of therapies based on microbiomes is receiving significant funding from biotech startups and pharmaceutical companies. One of the first microbiome startups in India, Xome Life Sciences, for example, focuses on every facet of the microbiome. The company is in the field and is developing prognostic, diagnostic, and therapeutic tools based on microbiomes to help people live healthier lives and make better decisions about their health. A recent FDA-approved treatment developed by Seres Therapeutics for recurrent Clostridium difficile infection is one of the many gastrointestinal diseases targeted by microbiome-based drugs. Vedanta Biosciences raised substantial money to build their pipeline of immunotherapies derived from microbiomes for autoimmune disorders and cancer. Notable investors such as Seventure Partners and Flagship Pioneering are actively funding companies that analyze microbiome data, reflecting a growing recognition of the microbiome's role in health. Thus, significant investment in research and development likely drives advancements in precision medicine and therapeutic interventions, thereby creating ample opportunities in the market.
The human microbiome market is segmented on the basis of type, application, disease type, and geography. The human microbiome market, based on type, is segmented into product and software and services. The product segment held a larger share of the human microbiome market in 2023, and it is expected to register a higher CAGR during 2023–2031. The human microbiome includes all microorganisms in and on the human body. These microbes have potential for use in disease management. Microbiome products show promise in treating severe conditions and personalizing therapy. The microbiota has been linked to neurological diseases, inflammatory diseases, and cancer.
Based on application, the market is segmented into therapeutics, diagnostics, and research. The therapeutics segment accounted for the largest share of the human microbiome market in 2023.
Based on disease type, the human microbiome market is segmented into obesity, diabetes, autoimmune disorders, cancer, GIT disorders, and others. The GIT disorders segment held the largest share of the human microbiome market in 2023. The significant metabolic potential of gut microbes and their role in maintaining human health is emerging, with new possibilities to utilize them as therapeutic agents for addressing human disorders. Microbiome therapeutics aim to manipulate the gut microbiome using additive, subtractive, or modulatory therapy with native or engineered microbes, antibiotics, bacteriophages, and bacteriocins. This approach has the potential to provide personalized, harmonized, reliable, and sustainable treatment, overcoming the limitations of conventional therapeutics. The economic potential of microbiome therapeutics has been demonstrated in the global therapeutics market. However, despite its promise, microbiome therapeutics is still in the developmental stage and faces various technical and administrative challenges requiring further research.
In terms of geography, the human microbiome market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). North America held the largest share of the human microbiome market in 2023. The market growth in North America is characterized by robust research activities on the human microbiome, increased funding for biotechnology, a rise in health consciousness among the population, and an increase in the demand for probiotics and prebiotics to treat chronic diseases. The applications of the human microbiome are rapidly growing in the field of biotechnology; it is emerging as a significant therapy to treat various chronic diseases. Research and development on human microbiome-based therapeutics has grown significantly in the US, leading to increased private investment and advances in environmental microbiome engineering.
Approximately 20% of this funding has been utilized for two phases of the Human Microbiome Project (HMP), which aims to create the necessary research resources for studying the human microbiome. HMP was launched in 2007 to establish a comprehensive toolbox consisting of reference data sets, computational techniques, analytical methods, and clinical protocols. This endeavor has proven to be successful, as roughly 75% of the NIH grant recipients for microbiome research from 2012 to 2016, working across more than 100 diseases, relied on HMP data and tools in their funding applications. Financed by the US National Institutes of Health (NIH), the HMP has significantly accelerated human microbiome research both within the US and on a global scale. The rise in research activities is likely to offer opportunities for the development of innovative therapies in the market.
MaaT Pharma; Ferring Holdings SA; Finch Therapeutics Group Inc; AOBiome Therapeutics Inc.; Seres Therapeutics Inc; Merck & Co Inc; Yakult Honsha Co., Ltd; Rebiotix; Inc; IFF Nutrition & Biosciences; and Synthetic Biologics, Inc are among the key players in the market.
Companies operating in the human microbiome market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the human microbiome market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.
A few of the developments made by the companies operating in human microbiome market are as follows:
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com